N-(2-(imidazo-4-yl)ethyl)-N'-(5-bromopyrid-2-yl)-thiourea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-(2-(imidazo-4-yl)ethyl)-N'-(5-bromopyrid-2-yl)-thiourea
• 英文别名: 1-(5-bromo-2-pyridyl)-3-[2-(1H-imidazol-4-yl)ethyl]thiourea；1-(5-bromopyridin-2-yl)-3-[2-(1H-imidazol-5-yl)ethyl]thiourea
• 化学式: C₁₁H₁₂BrN₅S
• 分子量: 326.22
• InChiKey: FRQSUVUISAXHFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  97.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  组胺 、 imidazole-1-carbothionic acid (5-bromopyridin-2-yl)amide 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 N-(2-(imidazo-4-yl)ethyl)-N'-(5-bromopyrid-2-yl)-thiourea
  参考文献：
  名称：

  N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of nni-resistant and multidrug-resistant human immunodeficiency virus-1

  摘要：

  The thiophene-ethyl thiourea (TET) compound N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridl)]-thiourea (compound HI-443) was five times more potent than trovirdine, 1250 times more potent than nevirapine, 100 times more potent than delavirdine, 75 times more potent than MKC-442, and 50 times more potent than AZT against the multidrug resistant HIV-1 strain RT-MDR with a V106A mutation. HI-443 was almost as potent against the NNI-resistant HIV-I strain A17 with a Y181C mutation as it was against HTLVIIIB. The activity of HI-443 against A17 was ten times more potent than that of trovirdine, 2083 times more potent than that of nevirapine, and 1042 times more potent than that of delavirdine. HI-443 inhibited the replication of the NNI-resistant HIV-1 strain A17 variant with Y181C plus K103N mutations in RT with an IC, value of 3.3 mu M, whereas the IC50 values of trovirdine, nevirapine, and delavirdine were all >100 mu M. These findings establish the novel thiophene containing thiourea compound HI-443 as a novel NNI with potent antiviral activity against NNI-sensitive, NNI-resistant and multidrug-resistant strains of HIV-l. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00624-1

文献信息

• Compounds and methods for inhibition of HIV and related viruses
  申请人：Medivir AB

  公开号：US20040116418A1

  公开（公告）日：2004-06-17

  The present invention is directed to compounds, compositions and methods of inhibiting and treating HIV and related viruses, and methods for cocrystallizing reverse transcriptase in vitro, inhibition of the replication of HIV and related viruses thereof.

  本发明涉及抑制和治疗HIV及相关病毒的化合物、组合物和方法，以及体外共结晶逆转录酶的方法，抑制HIV及相关病毒的复制。
• COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES
  申请人：MEDIVIR AB

  公开号：EP0706514A1

  公开（公告）日：1996-04-17
• US5849769A
  申请人：——

  公开号：US5849769A

  公开（公告）日：1998-12-15
• US6376492B1
  申请人：——

  公开号：US6376492B1

  公开（公告）日：2002-04-23
• [EN] COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES<br/>[FR] COMPOSITIONS ET PROCEDES D'INHIBITION DU VIH ET DE VIRUS APPARENTES
  申请人：MEDIVIR AB

  公开号：WO1995006034A1

  公开（公告）日：1995-03-02

  (EN) The present invention is directed to compounds, compositions and methods of inhibiting and treating HIV and related viruses, and methods for cocrystallizing reverse transcriptase $i(in vitro), inhibition of the replication of HIV and related viruses thereof.(FR) L'invention concerne des composés, des compositions et des procédés servant à inhiber et à traiter les infections à VIH et à virus apparentés, ainsi que des procédés de cocristallisation de la transcriptase reverse $i(in vitro), d'inhibition de la réplication du VIH et de virus apparentés.